FDA Approves Study of Ecstasy as Treatment for Post-Traumatic Stress Disorder 11/9/01

Drug War Chronicle, recent top items


recent blog posts "In the Trenches" activist feed


The Multidisciplinary Association for Psychedelic Studies (http://www.maps.org) announced on November 2 that it received approval from the Food and Drug Administration (FDA) for its protocol to test MDMA (ecstasy) in the treatment of post-traumatic stress disorder (PTSD). The FDA action marks the first approval of trials of ecstasy as a therapeutic agent since the drug was made illegal in 1985.

"The FDA called and informed me that the protocol had been approved," MAPS founder and head Rick Doblin told DRCNet. "This shows that the demonization of MDMA is not a complete barrier to the development of its potential therapeutic uses," said Doblin, who hopes to develop ecstasy and other psychedelics into prescription medicines.

If approved by a university review board, the trials will take place at the Medical University of South Carolina under the supervision of psychiatrist Dr. Michael Mithoefer and his wife Annie, a psychiatric nurse. The study protocol calls for 12 people suffering from PTSD to be given ecstasy as they go through therapy for their disorder. Eight others will be given a placebo. Both sets of patients will also undergo 16 hours of therapy without drugs.

Prior to the banning of ecstasy after it became popular as a party drug among Texas college students in the mid-1980s, researchers had used it in a variety of therapeutic contexts, including PTSD, marital counseling, and in grappling with fatal illnesses. But research came to a screeching halt with ecstasy prohibition.

Some people would like to keep it that way. Dr. Alan Leshner, the retiring head of the National Institute on Drug Abuse (NIDA) and leader of the anti-ecstasy scare campaign, told the Wall Street Journal the proposed study was a dangerous waste of time. "I know of no evidence in the scientific literature that demonstrates the efficacy of ecstasy for any clinical indication," he sputtered. "And we don't give drugs of abuse to naïve subjects except under extraordinary circumstances."

Rick Doblin doesn't suffer such talk gladly. "Leshner and NIDA are engaged in science in the service of the drug war, not a rational risk-benefit analysis. If Leshner says there is no evidence of MDMA's therapeutic potential, it's because they've blocked the research," Doblin argued. "As for giving drugs to naïve subjects, these are extraordinary circumstances. All of these are patients who have had PTSD for at least six months and have not responded to six months of serotonin specific reuptake inhibitors, such as Prozac."

Doblin also told DRCNet the FDA needs more attention from drug reformers. "The FDA is going to be an essential agency to work with; it can be a way for us to progress. With only $5 million, we could do the research to get marijuana through the FDA. The drug reform movement needs to expand its strategies to work with this agency," said Doblin. "If we can create a legal context for these drugs, that will demonstrate that there are indeed instances where people can use them."

And stricken by the magnanimity of the moment, Doblin even offered to help NIDA create responsible education about ecstasy. "Nobody believes MDMA is harmless; we all understand there are some risks," he said. "We would like to work together with NIDA to get education that can be believed, not the propaganda we get from NIDA under Leshner. We need to recognize that the way drug warriors exaggerate the risk of MDMA makes them vulnerable. They've been terrified of the medical research into its benefits, but they need to live with the drug as it is, not as they wish to paint it."

-- END --
Link to Drug War Facts
Please make a generous donation to support Drug War Chronicle in 2007!          

PERMISSION to reprint or redistribute any or all of the contents of Drug War Chronicle (formerly The Week Online with DRCNet is hereby granted. We ask that any use of these materials include proper credit and, where appropriate, a link to one or more of our web sites. If your publication customarily pays for publication, DRCNet requests checks payable to the organization. If your publication does not pay for materials, you are free to use the materials gratis. In all cases, we request notification for our records, including physical copies where material has appeared in print. Contact: StoptheDrugWar.org: the Drug Reform Coordination Network, P.O. Box 18402, Washington, DC 20036, (202) 293-8340 (voice), (202) 293-8344 (fax), e-mail [email protected]. Thank you.

Articles of a purely educational nature in Drug War Chronicle appear courtesy of the DRCNet Foundation, unless otherwise noted.

Issue #210, 11/9/01 Proposed Marijuana Penalty Increase at Ohio University Meets Stiff Student Opposition | FDA Approves Study of Ecstasy as Treatment for Post-Traumatic Stress Disorder | School Drug Testing Headed for Supreme Court Again | Walters Drug Czar Nomination Approved in Senate Committee Vote | Ashcroft Sics DEA on Oregon Suicide Doctors | Drug Reformers, Colombia, and the Anti-Terrorism Act | Indonesia Marches Backward on Drug Policy | Election Report: New York City Drug Reformers, Virginia Reams Reeferendum Buried by Anthrax and Terrorist Attacks | Amnesty International Drug War Resolution Passes Northeast Regional Conference, Goes on to National Meeting | Methadone and Cipro: Patients Needing Both Should Consult Physicians About Possible Drug Interaction | Massive Military Presence and Abuses Continue in Bolivia's Chapare Region | Journal of Cannabis Therapeutics Online | Alerts: HEA Drug Provision, Drug Czar Nomination, DEA Hemp Ban, Ecstasy Bill, Mandatory Minimums, Medical Marijuana | The Reformer's Calendar
Mail this article to a friend
Send us feedback on this article
This issue -- main page
This issue -- single-file printer version
Drug War Chronicle -- main page
Chronicle archives
Subscribe now!
Out from the Shadows HEA Drug Provision Drug War Chronicle Perry Fund DRCNet en EspaŮol Speakeasy Blogs About Us Home
Why Legalization? NJ Racial Profiling Archive Subscribe Donate DRCNet em PortuguÍs Latest News Drug Library Search
special friends links: SSDP - Flex Your Rights - IAL - Drug War Facts

StoptheDrugWar.org: the Drug Reform Coordination Network (DRCNet)
1623 Connecticut Ave., NW, 3rd Floor, Washington DC 20009 Phone (202) 293-8340 Fax (202) 293-8344 [email protected]